Novalis Biotech Incubation

Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation. Enzyre’s platform technology is unique as it requires just a small volume of blood and is able to measure up to twelve (12) biomarkers simultaneously without any laboratory infrastructure; at home, on the road or in a critical care setting. Enzyre’s proprietary technology is a small hand-held diagnostic tool using disease specific single use microfluidic cartridges with high sensitivity and specificity. It has broad applicability in several disease areas.

EXITED – Cergentis was acquired by Solvias

Cergentis is an innovative leader in genomics, provides kits and services based on its proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide.

Fertiga (fertiga.com) is a spin-off from Vrije Universiteit Brussel (VUB) on the basis of research carried out over the past 10 years within the VUB and University hospital of Brussels (UZ Brussels). Our objective is to become a major player in improving fertility treatment outcomes. We improve efficiency of IVF by analysis of gene expressions in cells surrounding the egg cell. Our goal is to reach ‘one child with one try’.

 DIVESTED

Epigenetic Biomarkers for Cancer Diagnosis and Personalized Treatment

Epify develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the course of the disease. Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and a better prognosis for cancer patients.

EXITED – Doc.ai was acquired by Sharecare

Doc.ai wants to break down data silos and transform healthcare with the power of artificial intelligence. End users can collect all their medical information in the doc.ai app.

myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond.

OhmX.bio is a spin-off initiative @ the Ghent University offering R&D through cutting-edge technologies to help our customers resolve their biological questions, providing a full trajectory from sample preparation to data analysis of the results. We offer next generation wet-lab solutions to our customers in the field of transcriptomics, translatomics, proteomics and epigenetics.

BioLizard (Lizard.Bio) is founded to provide bioinformatics solutions for customers in biotech, pharma and academia. As life science research is rapidly evolving into a more data-driven field, there is a niche and a high demand for this type of applications. Lizards adapt to their biological environment. Likewise, we strive towards offering state-of-the-art bioinformatics, statistics and machine learning solutions to help solve biological questions by adapting to the needs and data of our customers.